-
1.发明授权
公开(公告)号：EP3199547B1
公开(公告)日：2020-11-18
申请号：EP16205057.9
申请日：2012-03-28
申请人： SANOFI
-
2.发明公开DUAL VARIABLE REGION ANTIBODY-LIKE BINDING PROTEINS HAVING CROSS-OVER BINDING REGION ORIENTATION 审中-公开具有交叉结合区域取向的双变量区域抗体样结合蛋白
公开(公告)号：EP3199547A1
公开(公告)日：2017-08-02
申请号：EP16205057.9
申请日：2012-03-28
申请人： SANOFI
发明人： Baurin, Nicolas , Beil, Christian , Corvey, Carsten , Lange, Christian , Li, Danxi , Mikol, Vincent , Steinmetz, Anke , Ercole, Rao
摘要： The invention provides antibody-like binding proteins comprising four polypeptide chains that form four antigen binding sites, wherein each pair of polypeptides forming an antibody-like binding protein possesses dual variable domains having a crossover orientation. The invention also provides methods for making such antigen-like binding proteins.
摘要翻译： 本发明提供了包含形成四个抗原结合位点的四条多肽链的抗体样结合蛋白，其中形成抗体样结合蛋白的每对多肽具有具有交叉取向的双重可变结构域。 本发明还提供了制备这种抗原样结合蛋白的方法。
-
公开(公告)号：EP2359843A1
公开(公告)日：2011-08-24
申请号：EP10305070.4
申请日：2010-01-21
申请人： SANOFI
发明人： Sommerfeld, Mark , Schaefer, Hans-Ludwig , Boscheinen, Oliver , Habermann, Paul , Ercole, Rao , Dreyer, Matthias
CPC分类号： A61K38/1825 , A61K38/26 , A61K45/06 , C07K14/50 , C07K2319/30 , A61K2300/00
摘要： The invention is directed to a pharmaceutical composition containing at least one FGF-21 (fibroblast growth factor 21) compound, at least one GLP-1R (glucagon-like peptide-1 receptor) agonist and optionally at least one anti-diabetic drug and/or at least one DPP-4 (dipeptidyl peptidase-4) inhibitor for the treatment of at least one metabolic syndrome and/or atherosclerosis, in particular diabetes, dyslipidemia, obesity and/or adipositas.
-
-
搜索结果
3 条记录 (耗时 0.01 秒)
